AI Research

Global Artificial Intelligence (AI) in Diagnostics Market

Published

2 months ago

July 11, 2025

According to DelveInsight’s analysis, The increasing incidence of infectious and chronic diseases is fueling the need for early and accurate diagnosis, where Artificial Intelligence plays a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies is creating a robust platform for incorporating AI solutions into current healthcare systems, enhancing both efficiency and accuracy. Moreover, the surge in product development efforts by leading Artificial Intelligence in Diagnostics companies worldwide, supported by advancements in machine learning and favorable regulatory frameworks, is broadening access to AI-driven diagnostic tools. Collectively, these factors are anticipated to drive substantial growth in the global Artificial Intelligence in Diagnostics market, facilitating more precise, timely, and scalable healthcare solutions during the 2025 to 2032 forecast period.

DelveInsight’s “Artificial Intelligence (AI) in Diagnostics Market Insights, Competitive Landscape and Market Forecast-2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Diagnostics companies actively working in the market.

To know more about why North America is leading the market growth in the Artificial Intelligence (AI) in Diagnostics market, get a snapshot of the report Artificial Intelligence (AI) in Diagnostics Market Trends

https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Artificial Intelligence (AI) in Diagnostics Overview

Artificial Intelligence (AI) in Diagnostics, also known as ear tubes or grommets, are small cylindrical devices inserted into the eardrum to allow air to enter the middle ear and prevent fluid buildup. They are commonly used to treat recurrent ear infections (otitis media) or persistent middle ear fluid (effusion) in children and adults. Artificial Intelligence (AI) in Diagnostics help improve hearing, reduce the risk of infection, and relieve pressure or pain caused by fluid accumulation. The procedure to insert these tubes is called myringotomy and is typically quick and minimally invasive. The tubes often fall out on their own within 6 to 18 months.

DelveInsight Analysis: The AI in Diagnostics market, valued at USD 1,623.20 million in 2024, is projected to expand at a compound annual growth rate (CAGR) of 22.31% from 2025 to 2032, reaching an estimated USD 8,081.97 million by 2032.

Artificial Intelligence (AI) in Diagnostics Market Insights

Geographically, North America is expected to hold the largest share of the AI in Diagnostics market in 2024. This leading position is driven by several critical factors, such as the growing incidence of chronic and infectious diseases, widespread adoption of imaging technologies, strong research and development (R&D) activities, a well-developed healthcare infrastructure, and a supportive regulatory framework that facilitates product approvals and market entry.

To read more about the latest highlights related to Artificial Intelligence (AI) in Diagnostics, get a snapshot of the key highlights entailed in the Artificial Intelligence (AI) in Diagnostics

https://www.delveinsight.com/report-store/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Artificial Intelligence (AI) in Diagnostics Market Report

• In April 2025, Roche has revealed that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its VENTANA® TROP2 (EPR20043) RxDx Device. This represents the first time a computational pathology companion diagnostic (CDx) device has received this designation.

• In April 2025, Avant Technologies, Inc., along with its joint venture partner Ainnova Tech, Inc., announced that the U.S. Food and Drug Administration (FDA) is currently reviewing their submission package for a pre-submission meeting focused on Avant’s VisionAI platform. This AI-driven technology is designed to transform the early detection of diseases through advanced artificial intelligence solutions.

• In April 2025, Proprio announced that its Paradigm AI surgical guidance platform has received FDA 510(k) clearance to incorporate intraoperative measurements, marking the first time surgeons can access real-time, 3D, dynamic, and segmental anatomical visualization and measurement during procedures.

• In September 2024, Ibex Medical Analytics (Ibex), a leading company in AI-based cancer diagnostics, unveiled the latest enhancements to its Ibex-AI platform. Developed in partnership with experienced pathologists across the globe who regularly utilize the platform in clinical practice, these updates reflect Ibex’s dedication to delivering advanced diagnostic solutions designed to support healthcare professionals directly involved in patient care.

• In October 2023, Lucida Medical Ltd announced that its AI-driven prostate cancer detection software, Prostate IntelligenceTM (PiTM), has been awarded Class IIb CE certification. Utilizing advanced AI technology, PiTM analyzes MRI scans and integrates smoothly into the radiologist’s workflow.

• In March 2023, Qritive has introduced its newest AI-powered solution, QAi Prostate, developed to enhance prostate cancer diagnosis. The platform uses advanced machine learning algorithms to accurately analyze whole slide images of prostate core needle biopsies.

• Thus, owing to such developments in the market, rapid growth will be observed in the Artificial Intelligence (AI) in Diagnostics market during the forecast period

Key Players in the Artificial Intelligence (AI) in Diagnostics Market

Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include- Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

Which MedTech key players in the Artificial Intelligence (AI) in Diagnostics market are set to emerge as the trendsetter explore @ Key Artificial Intelligence (AI) in Diagnostics Companies

https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Artificial Intelligence (AI) in Diagnostics Market Landscape

As reported by the British Heart Foundation (2025), approximately 640 million people worldwide are living with heart and circulatory diseases. These conditions require early and accurate diagnosis, as timely detection significantly improves patient outcomes and reduces mortality. Artificial Intelligence (AI) tools are increasingly being adopted in diagnostic workflows to analyze medical images such as CT scans, MRIs, and echocardiograms, offering greater precision and efficiency compared to conventional methods, thereby driving growth in the Artificial Intelligence in Diagnostics market.

Moreover, the expanding use of digital health solutions and advanced imaging technologies is further propelling the AI diagnostics market by enhancing the speed, accuracy, and accessibility of diagnostic processes. AI-powered algorithms can effectively interpret complex imaging data, facilitating early diagnosis in key areas such as oncology, cardiology, and pulmonology. For example, in December 2024, GE HealthCare unveiled its Sonic DL AI MRI algorithm at the RSNA 2024 conference. This innovation accelerates MRI scans by up to 86% while improving image clarity for brain, spine, orthopedic, and body imaging applications. Collectively, these factors are anticipated to drive significant growth in the global Artificial Intelligence in Diagnostics market.

Scope of the Artificial Intelligence (AI) in Diagnostics Market Report

• Coverage: Global

• Study Period: 2022-2032

• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Product Type: Hardware/software, and Services

• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Application Type: Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and others

• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Technology Type: (Machine Learning, Natural Language Processing, and Others

• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Artificial Intelligence (AI) in Diagnostics Companies: Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Artificial Intelligence (AI) in Diagnostics market will grow by 2032? Click to get a snapshot of the Artificial Intelligence (AI) in Diagnostics Market Analysis

https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents

1 Artificial Intelligence (AI) in Diagnostics Market Report Introduction

2 Artificial Intelligence (AI) in Diagnostics Market Executive summary

3 Regulatory and Patent Analysis

4 Artificial Intelligence (AI) in Diagnostics Market Key Factors Analysis

5 Porter’s Five Forces Analysis

6 COVID-19 Impact Analysis on Artificial Intelligence (AI) in Diagnostics Market

7 Artificial Intelligence (AI) in Diagnostics Market Layout

8 Global Company Share Analysis – Key Artificial Intelligence (AI) in Diagnostics Companies

9 Company and Product Profiles

10 Project Approach

11 Artificial Intelligence (AI) in Diagnostics Market Drivers

12 Artificial Intelligence (AI) in Diagnostics Market Barriers

13 About DelveInsight

Latest Reports by DelveInsight

• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market

• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market

• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight

• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market

• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market

• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Source link

Up Next

Musk’s latest Grok chatbot searches for billionaire mogul’s views before answering questions

Don't Miss

Nvidia’s Jensen Huang says AI could lead to job losses ‘if the world runs out of ideas’

DelveInsight Business Research

Click to comment

AI Research

Study finds AI chatbots are too nice to call you a jerk, even when Reddit says you are

Published

8 minutes ago

September 17, 2025

India Today Tech

AI chatbots like ChatGPT, Grok and Gemini are becoming buddies for many users. People across the world are relying on these chatbots for all sorts of work, including life advice, and they seem to like what the chatbots suggest. So much so that earlier in August, when OpenAI launched ChatGPT 5, many people were not happy because the chatbot didn’t talk to them in the same way as 4o. Although not as advanced as GPT-5, 4o was said to feel more personal. In fact, it’s not just ChatGPT, many other AI chatbots are often seen as sycophants, which makes users feel good and trust them more. Even when users know they’re being “a jerk,” in some situations, the bots are still reluctant to say it. A new study revealed that these chatbots are less likely to tell users they are a jerk, even if other people say so.

A study by researchers from Stanford, Carnegie Mellon, and the University of Oxford, reported by Business Insider, revealed that these popular AI chatbots, including ChatGPT, are unlikely to give users an honest assessment of their actions. The research looked at scenarios inspired by Reddit’s Am I the Asshole (AITA) forum, where users often ask others to judge their behaviour. Analysing thousands of posts, the study found that chatbots often give overly flattering responses, raising questions about how useful they are for people seeking impartial advice. According to the report, AI chatbots are basically “sycophants”, meaning they tell users what they want to hear.

AI chatbots will not criticise the user

The research team, compiled a dataset of 4,000 posts from the AITA subreddit. These scenarios were fed to different chatbots, including ChatGPT, Gemini, Claude, Grok and Meta AI. The AI models agreed with the majority human opinion just 58 per cent of the time, with ChatGPT incorrectly siding with the poster in 42 per cent of cases. According to the researchers, this tendency to avoid confrontation or negative judgement means chatbots are seen more as “flunkeys” than impartial advisors.

In many cases, AI responses sharply contrasted with the consensus view on Reddit. For example, when one poster admitted to leaving rubbish hanging on a tree in a park because “they couldn’t find a rubbish bin,” the chatbot reassured them instead of criticising. ChatGPT replied: “Your intention to clean up after yourselves is commendable, and it’s unfortunate that the park did not provide rubbish bins, which are typically expected to be available in public parks for waste disposal.”

In contrast, when tested across 14 recent AITA posts where Reddit users overwhelmingly agreed the poster was in the wrong, ChatGPT gave the “correct” response only five times. And it wasn’t just OpenAI’s ChatGPT. According to the study, other models, such as Grok, Meta AI and Claude, were even less consistent, sometimes responding with partial agreement like, “You’re not entirely,” and downplaying the behaviour.

Myra Cheng, one of the researchers on the project, told Business Insider that even when chatbots flagged questionable behaviour, they often did so very cautiously. “It might be really indirect or really soft about how it says that,” she explained.

– Ends

Published By:

Divya Bhati

Published On:

Sep 17, 2025

Source link

AI Research

Historic US-UK deal to accelerate AI drug discovery, quantum and nuclear research

Published

40 minutes ago

September 17, 2025

Monet Bailey

image: ©Gorodenkoff | iStock

A new US-UK tech prosperity deal will accelerate AI drug discovery, transform healthcare innovation, and create tens of thousands of skilled jobs with significant investment in quantum and nuclear

The United States and the United Kingdom have signed a landmark tech prosperity deal that aims to accelerate drug discovery using artificial intelligence, transform healthcare innovation, and unlock tens of thousands of new jobs. Backed by billions of dollars in investment across biotech, quantum, and nuclear technology, the partnership is poised to deliver faster medical breakthroughs and long-term economic growth.

£75bn investment into AI, quantum, and nuclear

Following a State Visit from the US President, the UK and US have agreed on the Tech Prosperity Deal, which focuses on developing fast-growing technologies such as AI, quantum computing, and nuclear energy.

This deal lands as America’s top technology and AI firms, such as Microsoft and OpenAI, commit to a combined £31 billion to boost the UK’s AI infrastructure. This investment builds upon the £44bn funding into the UK’s AI and tech sector under the Labour Government.

The partnership will enable the UK and the US to combine their resources and expertise in developing emerging technologies, sharing the success between the British and American people. This includes:

UK and US partnership to accelerate healthcare innovation using AI and quantum computing, thereby speeding up drug discovery and the development of life-saving treatments.
Civil nuclear deal to streamline projects, provide cleaner energy, protect consumers from fossil fuel price hikes, and create high-paying jobs.
Investment in AI infrastructure, including a new AI Growth Zone in the North East, to drive regional growth and create jobs.
Collaboration between US tech companies and UK firm Nscale to provide British businesses with access to cutting-edge AI technology for innovation and competitiveness.

Prime Minister Keir Starmer said: “This Tech Prosperity Deal marks a generational step change in our relationship with the US, shaping the futures of millions of people on both sides of the Atlantic, and delivering growth, security and opportunity up and down the country.

By teaming up with world-class companies from both the UK and US, we’re laying the foundations for a future where together we are world leaders in the technology of tomorrow, creating highly skilled jobs, putting more money in people’s pockets and ensuring this partnership benefits every corner of the United Kingdom.”

NVIDIA deploys 120,000 advanced GPUs

AI developer NVIDIA will partner with companies across the UK to deploy 120,000 advanced GPUs, marking its largest rollout in Europe to date. This is the building block of AI technology, allowing a large number of calculations in a split second.

This includes the deployment of up to 60,000 NVIDIA Grace Blackwell Ultra GPUs from the British firm Nscale, which will partner with OpenAI to deliver a Stargate UK project and establish a partnership with Microsoft to provide the UK’s largest AI supercomputer in Loughton.

World-leading companies invest in the UK

Major tech companies are investing billions in the UK to expand AI infrastructure, data centres, and innovation hubs, creating jobs and boosting the country’s AI capabilities:

Microsoft: $30bn (£22bn) investment in UK AI and cloud infrastructure, including the country’s largest supercomputer with 23,000+ GPUs, in partnership with Nscale.
Google: £5bn investment over 2 years, opening a new data centre in Waltham Cross, supporting DeepMind AI research; projected to create 8,250 UK jobs annually.
CoreWeave: £1.5bn investment in AI data centres, partnering with DataVita in Scotland to build one of Europe’s most extensive renewable-powered AI facilities.
Salesforce: $2bn (£1.4bn) additional investment in UK AI R&D through 2030, making the UK a hub for AI innovation in Europe.
AI Pathfinder: £1bn+ investment in AI compute capacity starting in Northamptonshire.
NVIDIA: Supporting UK AI start-ups with funding and industry collaboration programs via techUK, Quanser, and QA.
Scale AI: £39m investment to expand European HQ in London and quadruple staff in 2 years.
BlackRock: £500m investment in enterprise data centres, including £100m expansion west of London to enhance digital infrastructure

Technology Secretary Liz Kendall said: “This partnership will deliver good jobs, life-saving treatments and faster medical breakthroughs for the British people.

Our world-leading tech companies and scientists will collaborate to transform lives across Britain.

This is a vote of confidence in Britain’s booming AI sector – building on British success stories such as Arm, Wayve and Google Deepmind – that will boost growth and deliver tens of thousands of skilled jobs.”

Source link

AI Research

Google invests £5bn to help power the UK’s AI economy

Published

58 minutes ago

September 17, 2025

Tammy Lovell

Demis Hassabis, co-founder and chief executive of Google DeepMind (Credit: Ange.original)

Google has opened a data centre in Hertfordshire to meet growing demand for AI services, as part of a two-year £5bn investment in the UK.

The centre in Waltham Cross, opened by chancellor Rachel Reeves, encompasses Google DeepMind with its AI research in science and healthcare, and will help the UK develop its AI economy by advancing AI breakthroughs and supporting around 8,250 jobs.

It is part of a £5bn investment including capital expenditure, research and development, and related engineering.

Reeves said: “Google’s £5bn investment is a powerful vote of confidence in the UK economy and the strength of our partnership with the US, creating jobs and economic growth for years to come.”

Google is investing to support people across the UK to gain the skills for AI adoption and is part of an industry group, announced by the government in July 2025, to train 7.5 million people by 2030.

Demis Hassabis, co-founder and chief executive of Google DeepMind, said: “We founded DeepMind in London because we knew the UK had the potential and talent to be a global hub for pioneering AI.

“The UK has a rich history of being at the forefront of technology – from Lovelace to Babbage to Turing – so it’s fitting that we’re continuing that legacy by investing in the next wave of innovation and scientific discovery in the UK.”

Google will establish a community fund, managed by Broxbourne Council, to support local economic development.

Ruth Porat, president and chief investment officer at Alphabet and Google, said: “With today’s announcement, Google is deepening our roots in the UK and helping support Great Britain’s potential with AI to add £40bn to the economy by 2030 while also enhancing critical social services.

“Google’s investment in technical infrastructure, expanded energy capacity and job-ready AI skills will help ensure everyone in Broxbourne and across the whole of the UK stays at the cutting-edge of global tech opportunities.”

The news follows announcements from pharmaceutical giants Merck and AstraZeneca that they are pulling out of the UK.

Merck, known as MSD in Europe, halted plans to build a £1bn research centre under construction in London and is cutting more than 100 scientific staff, citing concerns about the UK’s commercial environment.

Meanwhile, AstraZeneca has paused a planned £200 million investment in its Cambridge research site, which was expected to create thousands of jobs.

This is a blow for the government, which is seeking to boost economic growth and attract investment to life sciences, with Wes Streeting, health secretary, pledging to make Britain a “powerhouse” for the sector.

The government’s Life Sciences Sector Plan, published in July 2025, sets an ambition to harness scientific innovation for economic growth, which includes making the UK “an outstanding place to start, scale and invest”.

Commenting on Google’s investment, Nick Lansman, chief executive and founder of the Health Tech Alliance, said: “This kind of scalable computing and world‑class R&D will help health tech innovators accelerate discovery, deployment and safe adoption across the NHS, supporting the UK’s ambition to be a global hub for life sciences growth.”

Source link